GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nova Mentis Life Science Corp (OTCPK:NMLSF) » Definitions » Shiller PE Ratio

Nova Mentis Life Science (Nova Mentis Life Science) Shiller PE Ratio : (As of Jun. 08, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Nova Mentis Life Science Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nova Mentis Life Science Shiller PE Ratio Historical Data

The historical data trend for Nova Mentis Life Science's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nova Mentis Life Science Shiller PE Ratio Chart

Nova Mentis Life Science Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Nova Mentis Life Science Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Nova Mentis Life Science's Shiller PE Ratio

For the Biotechnology subindustry, Nova Mentis Life Science's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nova Mentis Life Science's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nova Mentis Life Science's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nova Mentis Life Science's Shiller PE Ratio falls into.



Nova Mentis Life Science Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nova Mentis Life Science's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Nova Mentis Life Science's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.001/126.2576*126.2576
=-0.001

Current CPI (Mar. 2024) = 126.2576.

Nova Mentis Life Science Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201312 -0.038 96.945 -0.049
201403 -0.014 98.604 -0.018
201406 -0.037 99.473 -0.047
201409 -0.036 99.394 -0.046
201412 -0.277 98.367 -0.356
201503 -0.032 99.789 -0.040
201506 -0.012 100.500 -0.015
201509 -0.030 100.421 -0.038
201512 -0.029 99.947 -0.037
201603 -0.005 101.054 -0.006
201606 -0.012 102.002 -0.015
201609 -0.012 101.765 -0.015
201612 -0.090 101.449 -0.112
201703 -0.010 102.634 -0.012
201706 -0.012 103.029 -0.015
201709 -0.033 103.345 -0.040
201712 -0.031 103.345 -0.038
201803 -0.062 105.004 -0.075
201806 -0.005 105.557 -0.006
201809 -0.031 105.636 -0.037
201812 0.000 105.399 0.000
201903 -0.007 106.979 -0.008
201906 -0.008 107.690 -0.009
201909 -0.008 107.611 -0.009
201912 0.000 107.769 0.000
202003 -0.007 107.927 -0.008
202006 -0.140 108.401 -0.163
202009 -0.008 108.164 -0.009
202012 -0.127 108.559 -0.148
202103 -0.008 110.298 -0.009
202106 -0.003 111.720 -0.003
202109 -0.008 112.905 -0.009
202112 0.000 113.774 0.000
202203 -0.008 117.646 -0.009
202206 -0.002 120.806 -0.002
202209 -0.002 120.648 -0.002
202212 -0.007 120.964 -0.007
202303 -0.003 122.702 -0.003
202309 -0.001 125.230 -0.001
202403 -0.001 126.258 -0.001

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nova Mentis Life Science  (OTCPK:NMLSF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nova Mentis Life Science Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nova Mentis Life Science's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nova Mentis Life Science (Nova Mentis Life Science) Business Description

Traded in Other Exchanges
Address
700-838 West Hastings Street, Vancouver, BC, CAN, V6C 0A6
Nova Mentis Life Science Corp is a Canadian-based biotechnology company. It is engaged in developing diagnostics and psilocybin-based therapeutics for neuroinflammatory disorders. Nova uses psilocybin in the treatment of Fragile X Syndrome (FXS). The company's goal is to diagnose and treat debilitating chronic conditions that have unmet medical needs such as autism spectrum disorder (ASD) and FXS. It has one industry segment, being research and development of psilocybin, and in one geographic area, which is Canada.

Nova Mentis Life Science (Nova Mentis Life Science) Headlines

From GuruFocus

U.S. FDA Approves Nova Mentis Orphan Drug Application

By PRNewswire PRNewswire 11-02-2021

Nova Mentis Begins Enrollment in North American Autism Study

By PRNewswire PRNewswire 03-23-2022

Nova Mentis Announces Closing of Non-Brokered Financing

By PRNewswire PRNewswire 03-15-2022